Dokument: Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data
| Titel: | Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data | |||||||
| URL für Lesezeichen: | https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=68008 | |||||||
| URN (NBN): | urn:nbn:de:hbz:061-20241219-120256-0 | |||||||
| Kollektion: | Publikationen | |||||||
| Sprache: | Englisch | |||||||
| Dokumententyp: | Wissenschaftliche Texte » Artikel, Aufsatz | |||||||
| Medientyp: | Text | |||||||
| Autoren: | Brockmeyer, Maximilian [Autor] Parco, Claudio [Autor] Vargas, Kris Gregory [Autor] Westenfeld, Ralf [Autor] Jung, Christian [Autor] Kelm, Malte [Autor] Roden, Michael [Autor] Akbulut, Cihan [Autor] Schlesinger, Sabrina [Autor] Wolff, Georg [Autor] | |||||||
| Dateien: |
| |||||||
| Stichwörter: | Composite renal outcome, Absolute treatment effect, GLP-1 receptor agonist, SGLT2 inhibitor | |||||||
| Beschreibung: | Background
Absolute treatment benefits—expressed as numbers needed to treat—of the glucose lowering and cardiovascular drugs, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose transporter 2 (SGLT2) inhibitors on renal outcomes remain uncertain. With the present meta-analysis of digitalized individual patient data, we aimed to display and compare numbers needed to treat of both drugs on a composite renal outcome. Methods From Kaplan–Meier plots of major cardiovascular outcome trials of GLP-1 receptor agonists and SGLT2 inhibitors vs. placebo, we digitalized individual patient time-to-event information on composite renal outcomes with WebPlotDigitizer 4.2; numbers needed to treat from individual cardiovascular outcome trials were estimated using parametric Weibull regression models and compared to original data. Random-effects meta-analysis generated meta-numbers needed to treat with 95% confidence intervals (CI). Results Twelve cardiovascular outcome trials (three for GLP-1 receptor agonists, nine for SGLT2 inhibitors) comprising 90,865 participants were included. Eight trials were conducted in primary type 2 diabetes populations, two in a primary heart failure and two in a primary chronic kidney disease population. Mean estimated glomerular filtration rate at baseline ranged between 37.3 and 85.3 ml/min/1.73 m2. Meta-analyses estimated meta-numbers needed to treat of 85 (95% CI 60; 145) for GLP-1 receptor agonists and 104 (95% CI 81; 147) for SGLT2 inhibitors for the composite renal outcome at the overall median follow-up time of 36 months. Conclusion The present meta-analysis of digitalized individual patient data revealed moderate and similar absolute treatment benefits of GLP-1 receptor agonists and SGLT2 inhibitors compared to placebo for a composite renal outcome. | |||||||
| Rechtliche Vermerke: | Originalveröffentlichung:
Brockmeyer, M., Parco, C., Vargas, K. G., Westenfeld, R., Jung, C., Kelm, M., Roden, M., Akbulut, C., Schlesinger, S., Wolff, G., & Kuß, O. (2024). Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data. Journal of Nephrology, 37(2), 309–321. https://doi.org/10.1007/s40620-023-01858-8 | |||||||
| Lizenz: |  Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung 4.0 International Lizenz | |||||||
| Fachbereich / Einrichtung: | Medizinische Fakultät | |||||||
| Dokument erstellt am: | 19.12.2024 | |||||||
| Dateien geändert am: | 19.12.2024 |
